Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Recruiting 2Completed 2Unknown 1Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1Neoplasms 1

Interventions

Specimen Handling 336Magnetic Resonance Spectroscopy 333Radiotherapy 315Cyclophosphamide 295pembrolizumab 282Cisplatin 266Carboplatin 245Drug Therapy 237Blood Specimen Collection 233Biopsy 206Bevacizumab 187Gemcitabine 177venetoclax 172Radiosurgery 169Capecitabine 165Oxaliplatin 163fludarabine 160Nivolumab 156Paclitaxel 155Standard of Care 137Surveys and Questionnaires 131Surgical Procedures, Operative 130Dexamethasone 127Fluorouracil 125Docetaxel 113tislelizumab 110Rituximab 110Cytarabine 104atezolizumab 101Azacitidine 101

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × OTHER × Postmortem Imaging × Clear all
NCT06906562 2026-02-17

A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations

Ohio State University Comprehensive Cancer Center

Phase 2 Recruiting
40 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT04814095 2025-09-25

PREDiCTc

British Columbia Cancer Agency

Phase NA Recruiting
30 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡